3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
1034
Neoplasms
815
Carcinoma, Non-Small-Cell Lung
799
Prostatic Neoplasms
621
Colorectal Neoplasms
529
Lung Neoplasms
486
Neoplasm Metastasis
434
Multiple Myeloma
395
Leukemia, Myeloid, Acute
391
Ovarian Neoplasms
334
Pancreatic Neoplasms
316
Melanoma
297
Squamous Cell Carcinoma of Head and Neck
268
Recurrence
256
Carcinoma, Hepatocellular
250
Glioblastoma
238
Brain Neoplasms
237
Triple Negative Breast Neoplasms
213
Carcinoma, Renal Cell
209
Head and Neck Neoplasms
208
Precursor Cell Lymphoblastic Leukemia-Lymphoma
201
Lymphoma
201
Stomach Neoplasms
197
Endometrial Neoplasms
189
Uterine Cervical Neoplasms
185
Lymphoma, Non-Hodgkin
180
Glioma
180
Sarcoma
179
Lymphoma, Large B-Cell, Diffuse
167
Hematologic Neoplasms
162
Interventions
zimberelimab
1
sacituzumab govitecan
1
pembrolizumab
1
enfortumab vedotin
1
avelumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Urothelial Cancer
×
90 days
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA